We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Developed for More Effective Noninvasive Prostate Cancer Screening

By LabMedica International staff writers
Posted on 16 Sep 2014
Print article
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Image: Researchers have demonstrated potential for a new, noninvasive method to screen for prostate cancer using a detection system that combines surface-enhanced Raman scattering (SERS) with support vector machine (SVM) techniques (Photo courtesy of Prof. S. Li and Guangdong Medical College).
Comparing healthy volunteers and prostate cancer (PrCa) patients, researchers have successfully shown that their new method, which builds on the use of SERS spectroscopy of silver nanoparticles mixed with blood samples, could reveal cases of cancer.

A team of researchers led by Prof. Shaoxin Li, of Guangdong Medical College (Guangdong province, China), has demonstrated potential of a new noninvasive method to screen for PrCa based on combining of the existing technique of serum surface-enhanced Raman scattering (SERS) with the new sophisticated analysis technique called support vector machine (SVM). Applying the combined SERS-SVM system to blood samples collected from 68 healthy volunteers and 93 people clinically confirmed to have PrCa, their technique identified the PrCa cases with 98.1% accuracy.

If the technique proves safe and effective in clinical trials, it may become an effective method available to patients and their doctors for improving early diagnosis of PrCa. “The results demonstrate that label-free serum SERS analysis combined with SVM diagnostic algorithm has great potential,” said Prof. Li, “Compared to traditional screening methods, this method has the advantages of being noninvasive, highly sensitive, and very simple.”

The blood test for elevated levels of PSA (prostate specific antigen) commonly used for PrCa screening and monitoring is far from perfect as elevated PSA levels can be caused by many factors unrelated to cancer. This contributes to over-diagnosis, uncomfortable tissue biopsies, and other unnecessary treatment, which can be costly and carry significant side-effects. Because of this, the US Preventative Services Task Force now recommends against PSA-based screening for PrCa.

Other scientists have considered applying SERS to cancer detection as it would seem to enable detection of the subtle marker signals. The challenge, said Prof. Li, was that the signal differences between the serum samples taken from the healthy volunteers and the PrCa patients were too subtle to detect. So his team employed also the powerful spectral data processing algorithm SVM – and found it to be effective. While the work is preliminary, it demonstrates that the method has good potential for PrCa screening. The next research step, added Prof. Li, is to refine the method and explore whether it can distinguish cancer staging.

The method, described by S. Li et al, was published in the journal Applied Physical Letters, September 2, 2014, online.

Related Links:

Guangdong Medical College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more